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Leanne Wilson-Fritch,1,2 Sarah Nicoloro,1,3 My Chouinard,1,3 Mitchell A. Lazar,4 Patricia C. Chui,4 
John Leszyk,3 Juerg Straubhaar,1 Michael P. Czech,1,3 and Silvia Corvera1,2
1Program in Molecular Medicine, 2Interdisciplinary Graduate Program, and 3Department of Biochemistry and Molecular Pharmacology,  
University of Massachusetts Medical School, Worcester, Massachusetts, USA. 4Division of Endocrinology, Diabetes and Metabolism,  
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Adipose tissue plays a central role in the control of energy homeostasis through the storage and turnover of 
triglycerides and through the secretion of factors that affect satiety and fuel utilization. Agents that enhance 
insulin sensitivity, such as rosiglitazone, appear to exert their therapeutic effect through adipose tissue, but 
the precise mechanisms of their actions are unclear. Rosiglitazone changes the morphological features and 
protein profiles of mitochondria in 3T3-L1 adipocytes. To examine the relevance of these effects in vivo, we 
studied white adipocytes from ob/ob mice during the development of obesity and after treatment with rosigli-
tazone. The levels of approximately 50% of gene transcripts encoding mitochondrial proteins were decreased 
with the onset of obesity. About half of those genes were upregulated after treatment with rosiglitazone, and 
this was accompanied by an increase in mitochondrial mass and changes in mitochondrial structure. Func-
tionally, adipocytes from rosiglitazone-treated mice displayed markedly enhanced oxygen consumption and 
significantly increased palmitate oxidation. These data reveal mitochondrial remodeling and increased energy 
expenditure in white fat in response to rosiglitazone treatment in vivo and suggest that enhanced lipid utiliza-
tion in this tissue may affect whole-body energy homeostasis and insulin sensitivity.
Introduction
The ability of brown adipose tissue to affect whole-body metabo-
lism upon thermogenic stress has been known for many years (1, 2). 
More recently, the important contribution of white adipose tissue 
(WAT) to the control of energy homeostasis has been recognized 
with the study of tissue-specific knockout models and the discovery 
of adipocyte-specific secreted factors that have powerful effects on 
fuel metabolism (3, 4). These observations have raised many as-yet-
unanswered questions about the mechanisms by which adipocytes 
maintain their energy homeostasis as well as sense and respond to 
the metabolic requirements of the organism.
Brown adipocytes contain a large complement of mitochondria 
that serve as a source of heat generated as a consequence of flow 
through the electron transport chain under uncoupled conditions 
elicited by uncoupling protein 1 (UCP-1). Recently we reported 
that adipogenesis of the 3T3-L1 cell line, representative of white 
adipocytes, is also accompanied by a stimulation of mitochondrial 
biogenesis (5). The need for a large mitochondrial mass in white 
fat can be linked to key functions of the adipocyte that require 
mitochondrial function. For example, adipocytes must gener-
ate glycerol 3-phosphate at a rate sufficient to sustain triglyc-
eride synthesis, and for this the glyceroneogenic pathway and 
mitochondrial anaplerosis are critical (6, 7). In addition, the gen-
eration of acetyl-CoA for fatty acid activation prior to esterifica-
tion into triglycerides may require a relatively large mitochondrial 
mass. Moreover, β-oxidation of fatty acids may be an important 
source of energy in the fat cell.
To further explore the role of white fat mitochondria, we have 
studied their abundance, composition, and morphology in cells 
derived from the epididymal fat pads of ob/ob mice. In addition, 
we have analyzed the expression levels of mitochondrial genes in 
these cells. We found a profound decrease in the levels of tran-
scripts for nuclear-encoded mitochondrial genes accompanying 
the onset of obesity. Strikingly, rosiglitazone treatment of ob/ob 
mice reversed these effects and induced the expression of a set 
of genes normally silent in adipocytes from untreated animals. 
Direct analysis of the protein composition of mitochondria 
from rosiglitazone-treated animals mostly confirmed the infor-
mation derived from RNA abundance measurements, but also 
revealed large changes in some proteins that were not reflected 
by their transcript levels. Functionally, these changes were appar-
ent in the altered morphology of mitochondria as well as in the 
enhanced capacity of isolated cells to consume oxygen and oxi-
dize palmitate. These studies provide new hypotheses to explain 
some of the therapeutic actions of rosiglitazone.
Results
Previous studies conducted in 3T3-L1 adipocytes revealed the 
induction of mitochondrial biogenesis during the process of 
differentiation, suggesting an important role for mitochondrial 
mass in white adipocyte function. Furthermore, exposure of fully 
differentiated 3T3-L1 adipocytes to rosiglitazone led to pro-
nounced changes in mitochondrial morphology and to a small 
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but significant increase in mitochondrial mass. We searched for 
evidence for mitochondrial plasticity in vivo in white adipocytes 
isolated during the development of obesity and in response to 
rosiglitazone in ob/ob mice.
Age-matched C57BL/6J and ob/ob mice were used in this study. 
The effectiveness of rosiglitazone treatment was evidenced by the 
blood glucose concentration of ob/ob mice, which decreased to that 
seen in age-matched C57BL/6J mice (Figure 1, left). During the 2 
weeks of treatment of ob/ob mice with rosiglitazone, a small but 
statistically significant increase in body weight was detected (Figure 
1, middle). Interestingly, while epididymal fat pad mass increased 
considerably between 4 and 26 weeks of age in ob/ob animals, no 
statistically significant difference was detected in fat pad mass after 
rosiglitazone treatment (Figure 1, right).
Isolated adipocytes were obtained from epididymal fat pads 
from 26-week-old ob/ob mice and age-matched C57BL/6J mice 
and were analyzed by fluorescence microscopy with an antibody 
against the mitochondrial chaperone mHsp70 (Figure 2). Cells 
obtained from 26-week-old ob/ob mice were significantly 
larger than cells from age-matched C57BL/6J animals. 
In both cases, mitochondrial staining with anti-mHsp70 
appeared as a punctate pattern distributed throughout 
the cytoplasm of the cell, with an increase in concentra-
tion near the perinuclear region, where the cytoplasmic 
volume is greatest. The average fluorescence intensities 
per cell from projected three-dimensional image stacks 
were 0.53, 1.05, and 1.58 units for C57BL6/J and ob/ob 
mice and for ob/ob mice after rosiglitazone treatment. However, 
cells from ob/ob mice had approximately twice the diameter of, and 
thus a surface area 4 times and volume 8 times larger than, cells 
from C57BL6/J mice. Assuming a requirement for mitochondrial 
mass proportional to cell size, these results indicate a deficit in 
mHsp70 staining in cells from ob/ob mice relative to that of con-
trols. Because average cell size did not differ between ob/ob and 
rosiglitazone-treated ob/ob mice, these results indicate an increase 
of approximately 50% in staining in cells from rosiglitazone-treat-
ed mice. The staining pattern of cells from rosiglitazone-treated 
animals differed markedly from that of cells from untreated ob/ob 
mice in that it revealed a fine reticular pattern, also distributed 
throughout the cytoplasmic volume but significantly more con-
centrated in the perinuclear region (Figure 2). In addition, dense 
mitochondrial staining was observed surrounding small, drop-
let-like structures found in many cells from rosiglitazone-treated 
mice. The changes in mitochondrial density and morphology were 
also seen in cells stained with anti-mHsp60 (Figure 3); cells from 
rosiglitazone-treated animals contained almost twice the amount 
of mHsp60 per cell relative to cells from untreated animals. It is 
relevant that the staining pattern found in adipocytes from rosi-
glitazone-treated animals was seen in cells of a size equal to those 
from 26-week-old untreated animals, a finding that suggests that 
not only small cells (8) but also large cells within the adipose tissue 
are susceptible to the actions of rosiglitazone.
To rule out the possibility that the changes described above were 
due to rosiglitazone-induced alterations in mitochondrial chaper-
ones, rather than to changes in true mitochondrial mass, we imaged 
live isolated adipocytes after incubating them with a specific indi-
cator of mitochondrial mass, MitoTracker green. Mitochondria 
in age-matched C57BL/6J mice and 26-week-old ob/ob animals 
appeared as discrete punctate structures, while mitochondria in 
cells from ob/ob mice treated with rosiglitazone were reticular and 
surrounded what appeared to be small lipid droplets present in 
many cells (Figure 4). Thus, rosiglitazone treatment in vivo results 
in pronounced changes in global mitochondrial mass and mor-
phology. The presence of what appeared to be small lipid droplets 
surrounded by mitochondria suggests that considerable rearrange-
ments of the lipid-metabolizing machinery of the white adipocyte 
occur in response to PPARγ stimulation by rosiglitazone.
Figure 1
Effects of rosiglitazone on ob/ob mice. Fasting blood glucose concen-
trations, whole-body weight, and isolated fat pad weight were obtained 
in control animals or animals treated with rosiglitazone (Rosi) for 14 
days. Data were derived from 10 independent experiments in which 
2–5 mice of each condition were used.
Figure 2
Immunofluorescence analysis of mitochondrial Hsp70. 
Adipocytes were isolated from the epididymal fat pads of 26-
week-old C57BL/6J, ob/ob, and rosiglitazone-treated ob/ob 
(ob/ob + Rosi) mice. Adipocytes were fixed and stained and 
image stacks were obtained with a conventional wide-field 
microscope fitted with a 40× or 100× Nikon plan-apo objec-
tive. Images represent single optical sections. White arrows 
indicate small, droplet-like structures seen only in rosigli-
tazone-treated cells.
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To probe for the molecular basis of these morphological altera-
tions, we surveyed a database of RNA expression levels obtained 
using Affymetrix chips (Figure 5). Of the approximately 36,000 
genes and expressed sequence tag clusters in the murine genome 
U74v2 probe set, 11,949 were detected as present in cells from 4- 
and 26-week-old ob/ob mice. The level of expression of 4,560 (38%) 
of these genes differed between samples from 4- and 26-week-old 
mice. Of these, 2,245 (about 19%) were increased in transcript level 
and 2,315 (about 19%) were decreased. The database was then 
“queried” using a list of 700 probe sets previously annotated as 
“mitochondrial” in the Affymetrix database. Of these probe sets, 
373 detected genes present in cells from 4- and 26-week-old ob/ob 
mice. Approximately 204 (55%) of these were significantly altered 
by the onset of obesity, with 23 (6%) of genes found to be increased 
and 181 (49%) found to be decreased. These results suggested that 
genes related to mitochondrial structure and function are over-
represented in the group of genes that decrease in expression level 
during the onset of obesity.
To determine how specifically this overrepresentation relates to 
genes of the mitochondria compared with those of other organ-
elles, we used two additional lists of probe sets to “query” the 
database. One set consisted of 513 probe sets annotat-
ed with the term “endoplasmic reticulum” and anoth-
er set consisted of 802 probe sets annotated with the 
term “nuclear.” The “endoplasmic reticulum” probe set 
detected 249 genes present in cells from 4- and 26-week-old ob/
ob mice. Of these, 99 (40%) differed between samples from 4- and 
26- week-old mice, with 47 (19%) increased and 52 (21%) decreased. 
The “nuclear” probe set detected 353 genes, of which 123 (35%) 
differed between samples from 4- and 26-week-old mice, with 57 
(16%) increased and 66 (19%) decreased. This similar frequency of 
genes displaying increased or decreased expression levels in the 
“endoplasmic reticulum” and “nuclear” probe set is similar to that 
seen for the “all-gene” probe set, but different from that seen for 
the “mitochondrial” set, for which genes displaying decreases in 
expression levels were 7–8 times more frequent than those display-
ing increases in expression levels.
The changes occurring after treatment with rosiglitazone in 26-
week-old mice were also analyzed (Figure 5). In the U75 probe set, 
12,808 genes were detected as being present in cells from 26-week-
old ob/ob mice. The levels of expression of 1,539 (12%) of these were 
altered by exposure to rosiglitazone. The expression levels of 1,102 
(9%) were increased and 437 (3.4%) were decreased. The database 
was then “queried” with the same organelle-specific probe set lists 
described above. Of the probe sets annotated as “mitochondrial,” 
403 detected genes expressed in cells from 26-week-old ob/ob ani-
mals. Of these, 131 (32%) were altered by rosiglitazone treatment, 
with 130 (32%) displaying increased expression levels and only 1 
(0.2%) displaying a decreased expression level. Thus, genes associ-
ated with mitochondria are disproportionately affected by rosi-
glitazone treatment, with a strong bias toward an increase in gene 
expression. In contrast, other organelle-related genes displayed 
changes similar to those displayed by the total gene pool. Of the 
“endoplasmic reticulum” genes, 255 were detected in cells from 26-
week-old animals. Of these, 28 (11%) were altered by rosiglitazone 
treatment, with 18 (7%) displaying increased expression and 10 (4%) 
displaying decreased expression. Similarly, 391 “nuclear” genes 
were detected in cells from 26-week-old animals. Of these, 53 (14%) 
were altered by rosiglitazone treatment, with 41 (11%) displaying 
increased expression and 12 (3%) displaying decreased expression.
In addition to causing a disproportionate increase in the expres-
sion of existing mRNAs for mitochondrial genes, rosiglitazone 
induced the expression of approximately 100 genes that were not 
detected in white adipocytes from 26-week-old ob/ob mice. Among 
these are mitochondrial genes that would be expected to strongly 
influence energy metabolism and fatty acid oxidation and that 
are typically present in brown but not white adipocytes (Table 1). 
These include UCP-1, Cidea (9), and the M isoform of carnitine 
palmitoyltransferase I (10, 11).
Figure 3
Immunofluorescence analysis of mitochondrial Hsp60. Isolated 
adipocytes from age-matched untreated and rosiglitazone-treated 
 ob/ob mice were fixed, stained, and imaged with a conventional wide-
field microscope fitted with a 40× or 100× Nikon plan-apo objective. 
Cell fluorescence intensity and statistical analyses were measured as 
described in Methods. IOD, integrated optical density.
Figure 4
Live cell imaging of mitochondria with MitoTracker Green 
FM. Adipocytes were isolated from epididymal fat pads of 
26-week-old C57BL/6J or ob/ob mice that were either left 
untreated or were treated with rosiglitazone for 14 days. 
Cells were incubated with 100 nM MitoTracker Green FM 
for 30 minutes and 25 μl of the cell suspension was placed 
on a microscope slide. A glass coverslip was floated on the 
cell suspension and images were acquired within 5 minutes 
using a conventional wide-field microscope fitted with a ×40 
or ×100 Nikon plan-apo objective.
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To survey the degree of concordance between the changes in 
mRNA levels and changes at the protein level, we purified mito-
chondria from isolated adipocytes, solubilized them, and analyzed 
them by sucrose gradient centrifugation and SDS-PAGE. When 
normalized to the initial protein content of the cell homogenates 
from which mitochondria were isolated, the yield of mitochondrial 
protein was approximately double from cells from rosiglitazone-
treated ob/ob mice compared with untreated age-matched controls. 
This increase yield is consistent with the doubling of mitochondrial 
mass on a per-cell basis deduced by mitochondrial staining (Figure 
2). The more abundant proteins that displayed changes in response 
to rosiglitazone were excised and identified by mass spectrometry 
(Figure 6). We then “queried” the Affymetrix dataset to deter-
mine the expression pattern of the mRNAs for these spe-
cific proteins (Table 2). As expected, concordant increases in 
protein and mRNA levels in response to rosiglitazone were 
observed for many of the proteins identified by mass spec-
trometry. However, the increases in protein abundance exceed-
ed the increased level of expression detected by the Affymetrix 
chip analysis in several instances. For example, a 2- to 3-fold 
increase in protein levels of malate dehydrogenase (Mor1) 
corresponded to a 1.45-fold increase in mRNA abundance. 
More strikingly, the mitochondrial chaperones mHsp70 and 
mHsp60 were not “scored” as present in mouse adipose cells 
in the Affymetrix chip despite being abundant mitochondrial 
proteins, as judged by mass spectrometry. Moreover, the rosi-
glitazone-induced increase in the level of chaperone expres-
sion, which was evident both by mass spectrometry (Figure 
6) and Western blotting (Figure 7), was not detected by the 
Affymetrix chip analysis. This discordance suggests that 
mitochondrial protein expression may be particularly subject 
to regulation at the post-translational level and that some of 
the actions of rosiglitazone on mitochondrial structure/func-
tion may take place through translational control.
Among the proteins increased in response to rosiglitazone 
are several key proteins of the fatty acid β-oxidation pathway. 
Notably, the protein levels of short-chain, medium-chain, 
long-chain, and very-long-chain acyl-CoA dehydrogenases, 
which catalyze the key reaction in the β-oxidation of fatty 
acids, were found to be increased by rosiglitazone. Reducing equiva-
lents from these dehydrogenases are transported to the main respi-
ratory chain by the electron transfer flavoprotein, composed of two 
subunits, Etfa and Etfb, and by the electron transfer flavoprotein 
dehydrogenase Etfdh (12). The levels of all three of these proteins 
were detected to be increased by mass spectrometry and Affymetrix 
chip analysis. These results suggest that β-oxidation of fatty acids 
might be increased in response to rosiglitazone. To directly test 
this hypothesis, we measured the conversion of [14C]palmitate to 
[14C]O2 by isolated adipocytes derived from control and ob/ob mice. 
A significant increase in palmitate oxidation was detected in cells 
from rosiglitazone-treated animals (Figure 8).
Additional evidence for the functional relevance of the 
observed alterations in mitochondrial mass and composition 
in obesity is the marked depression in oxygen consumption 
by isolated adipocytes from ob/ob mice compared with that of 
cells from 4-week-old ob/ob animals (Figure 9) or age-matched 
C57BL/6J mice (data not shown). This depressed oxygen con-
sumption rate was almost completely reversed in cells from rosi-
glitazone-treated mice (Figure 9).
To investigate the potential mechanisms involved in the 
observed changes in mitochondrial mass and function in 
response to rosiglitazone, we analyzed the levels of PGC-1α (Fig-
ure 10). While the transcript levels for this coactivator were below 
the limits of detection in the Affymetrix chip, direct Northern 
Figure 5
Analysis of gene expression changes in adipocytes from ob/ob mice. 
Total RNA was extracted from isolated adipocytes from 4-week-old (4 
week) untreated, 26-week-old (26 week) untreated, and 26-week-old 
rosiglitazone-treated ob/ob mice and was used to probe the murine 
U74v2 Affymetrix GeneChip. The resulting data were queried using 
probe annotations within the Affymetrix database. vs., versus.
Table 1
Rosiglitazone-induced mitochondrial gene expression in ob/ob mouse 
adipocytes
Gene name Gene symbol FC Call Change
Uncoupling protein 1, mitochondrial Ucp1 20.63 P I
Uncoupling protein 1, mitochondrial Ucp1 21.61 P I
Uncoupling protein 1, mitochondrial Ucp1 4.7 P I
Uncoupling protein 1, mitochondrial Ucp1 4.7 P I
Cytochrome c oxidase, subunit VIIIb Cox8b 4.29 P I
Cytochrome c oxidase, subunit VIIIb Cox8b 3.25 P I
Cytochrome c oxidase, subunit VIIa 1 Cox7a1 5.53 P I
Pyruvate carboxylase Pcx 3.17 P I
Pyruvate carboxylase Pcx 2.58 P I
Isocitrate dehydrogenase 3 (NAD+) β Idh3b 2.52 P I
Isocitrate dehydrogenase 3 (NAD+) β Idh3b 2.46 P I
Electron transfer flavoprotein Etfdh 2.35 P I
 dehydrogenase
Cytochrome c, somatic Cycs 2.35 P I
Carnitine palmitoyltransferase 1, muscle Cpt1b 4.92 P I
Carnitine palmitoyltransferase 1, muscle Cpt1b 4.7 P I
The genes listed were expressed at levels low enough to qualify as absent from 
the cells from 4-week-old and 26-week-old ob/ob mice but present in those 
from 26-week-old rosiglitazone-treated mice. FC, “fold change” in gene expres-
sion; Call, presence (P) or absence (A) of probe on the GeneChip; Change, 
increase (I) or lack of change (NC) in expression in response to rosiglitazone.
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blotting revealed a signal for PGC-1α, which was increased sig-
nificantly in response to rosiglitazone.
Discussion
The use of the thiazolidinediones rosiglitazone and pioglitazone 
for the treatment of type 2 diabetes is firmly established. Both 
drugs result in a net improvement in insulin sensitivity, and 
recent evidence suggests beneficial effects of these drugs on car-
diovascular parameters associated with metabolic syndrome and 
type 2 diabetes complications (13, 14). The mechanism of action 
of rosiglitazone and pioglitazone is centered on their ability to 
activate PPARγ, which is abundantly expressed in adipose tissue 
and is present in vasculature, colonic epithelium, and leuko-
cytes. However, the relationship between PPARγ activation and 
the physiological and therapeutic actions of the glitazones is not 
completely clear. The work presented here suggests that rosi-
glitazone, presumably through its stimulatory effect on PPARγ, 
induces mitochondrial biogenesis and remodeling in WAT in a 
way that enhances fatty acid oxidation and markedly enhances 
oxygen consumption. This effect of rosiglitazone can be envi-
sioned to contribute directly and indirectly to changes in whole-
body energy metabolism and insulin sensitivity.
The salient effects of rosiglitazone treatment were a doubling 
of total mitochondrial mass and the additionally increased levels 
of mitochondrial proteins expected to enhance glyceroneogenesis, 
fatty acid transport into the mitochondrial matrix, fatty acid oxi-
dation, and electron transport. In addition, further enhanced flux 
through the electron transport chain would be expected to result 
from the greatly increased UCP-1 message levels. The consequenc-
es of these changes are evidenced functionally by the increase in 
palmitate oxidation and greatly enhanced rate of oxygen con-
sumption by isolated adipocytes from rosiglitazone-treated ani-
mals. These results raise two important questions. First, does this 
effect of rosiglitazone on white fat mitochondrial mass and energy 
metabolism lead to the enhancement of whole-body insulin sen-
sitivity that is the hallmark of the drug’s therapeutic effect? Sec-
Table 2
The mRNA expression levels of proteins identified by mass spectrometry
Accession number Gene name Gene symbol Affymetrix probe sets FC Call Change
477004 Epoxide hydrolase 2, cytoplasmic Ephx2 93051_at 4.39 P I
200246 Pyruvate carboxylase Pcx 93308_s_at 1.29 P I
200246 Pyruvate carboxylase Pcx AFFX-PyruCarbMur/L09192_3_at 1.29 P NC
200246 Pyruvate carboxylase Pcx AFFX-PyruCarbMur/L09192_5_at 3.17 P I
200246 Pyruvate carboxylase Pcx AFFX-PyruCarbMur/L09192_MA_at 2.58 P I
200246 Pyruvate carboxylase Pcx AFFX-PyruCarbMur/L09192_MB_at 2.05 P I
200246 Pyruvate carboxylase Pcx 162288_f_at 1.05 P NC
200246 Pyruvate carboxylase Pcx 168162_f_at 1.35 P NC
200246 Pyruvate carboxylase Pcx 171076_i_at –2.14 A NC
21313290 Electron transferring flavoprotein, dehydrogenase Etfdh 97869_at 2.35 P I
13385680 2,4,-Dienoyl-CoA reductase Decr1 115824_at; 160711_at 1.9 P I
19684166 Acyl-coenzyme A dehydrogenase, short chain Acads 103401_at 1.87 P I
19684166 Acyl-coenzyme A dehydrogenase, short chain Acads 161469_r_at –1.15 P NC
19684166 Acyl-coenzyme A dehydrogenase, short chain Acadsb 162725_at 1.12 P NC
32130423 Acetyl-coenzyme A dehydrogenase, long-chain Acadl 95425_at 1.82 P I
21759113 Electron transferring flavoprotein, alpha polypeptide Etfa 96112_at 1.82 P I
5304852 Aconitase 2, mitochondrial Aco2 96870_at 1.62 P I
181575 Dihydrolipoamide dehydrogenase Dld 97502_at 1.48 P I
42476181 Malate dehydrogenase, mitochondrial Mor1 93991_at 1.45 P I
21431780 L-3-hydroxyacyl-CoA dehydrogenase, short chain Hadhsc 95485_at 1.45 P I
13386272 Citrate synthase Cs 99666_at 1.38 P I
13386272 Citrate synthase Cs 164575_f_at 1.87 A I
30583785 Isocitrate dehydrogenase 3 (NAD+) alpha Idh3a 94534_at 1.35 P I
30583785 Isocitrate dehydrogenase 3 (NAD+) alpha Idh3a 169744_i_at –1.02 A NC
30583785 Isocitrate dehydrogenase 3 (NAD+) alpha Idh3a 170915_r_at –1.07 A NC
29351581 Electron transferring flavoprotein, beta polypeptide Etfb 162144_at –1.38 A NC
29351581 Electron transferring flavoprotein, beta polypeptide Etfb 96947_at 1.35 P NC
6678970 Methylmalonyl-coenzyme A mutase Mut 99613_at 1.23 P I
23956084 Acyl-coenzyme A dehydrogenase, very long chain Acadvl 161623_at –1.91 A NC
23956084 Acyl-coenzyme A dehydrogenase, very long chain Acadvl 93334_at 1.18 A NC
6753036 Aldehyde dehydrogenase 2, mitochondrial Aldh2 96057_at 1.07 P NC
6753036 Aldehyde dehydrogenase 2, mitochondrial Aldh2 96058_s_at 1.05 P NC
729927 Fatty acid coenzyme A ligase, long chain 2 Facl2 94507_at 1.05 P NC
14917005 mHsp70 Hspa9a 97914_at 2.19 A NC
14917005 mHsp70 Hspa9a 170001_at 1.26 P I
14917005 mHsp70 Hspa9a 171404_r_at 1.15 A NC
17391295 mHsp60 Hspd1 161140_r_at 1.41 P NC
17391295 mHsp60 Hspd1 93277_at –1.2 A NC
The Affymetrix GeneChip database was queried for the genes encoding the proteins identified by mass spectrometry described in Figure 5. 
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ond, what is the molecular basis for the effect of rosiglitazone on 
mitochondrial mass and patterning?
Numerous lines of evidence support the notion that increased 
circulating free fatty acids (FFAs) directly cause insulin resistance. 
The levels of circulating FFAs are influenced not only by the rate 
of triglyceride lipolysis but also by the rate of re-esterification and 
oxidation within the fat cell (15). Indeed, it has been calculated that 
as much as 40% of FFAs are re-esterified after lipolysis in adipose 
tissue from lean adults (16). The re-esterification rate appears to 
be rate limited by the levels of enzymes of glyceroneogenesis, as it 
is greatly increased by tissue-specific overexpression of phospho-
enolpyruvate carboxykinase (PEPCK). These precedents suggest 
that the glyceroneogenesis pathway may be rate limiting for FFA 
re-esterification and the enhancement of mitochondrial mass by 
rosiglitazone is likely to result in enhanced production of glyce-
roneogenic substrates and re-esterification. Indeed, an additional 
increase in the protein levels of pyruvate kinase within purified 
mitochondria was seen in this study (Figure 6), and re-esterification 
in response to rosiglitazone has been observed in adipocytes from 
rosiglitazone-treated ob/ob animals (S. Corvera and M.P. Czech, 
unpublished observations).
In addition to enhancement of re-esterification, an important 
effect of rosiglitazone on fatty acid oxidation cannot be ruled out 
and is supported by the results obtained in this study. In our exper-
iments, adipocytes from rosiglitazone-treated animals displayed 
an increase of about 30% in palmitate oxidation, a value that is 
likely to be an underestimate of the true effect of rosiglitazone in 
the face of enhanced triglyceride/fatty acid cycling. The fraction of 
FFAs that are oxidized within the fat cell has been measured to be 
only 0.2% of that produced by lipolysis. However, this increases to 
0.5% during fasting and is highly suppressed by insulin (15). More-
over, the high capacity for white fat to oxidize fatty acids under 
hyperleptinemic conditions has been reported (17). Thus, FFA oxi-
dation in WAT is regulated, and a thiazolidinedione-induced shift 
toward an increase oxidation over time could have a pronounced 
effect on circulating FFA levels and whole-body insulin sensitivity. 
Interestingly, a previously observed unusual finding is the accu-
mulation of 22:6n3 and other long-chain polyunsaturated fatty 
acids in the triglyceride pool of adipose tissue in response to rosi-
glitazone (18). This unusual response may be explained by the fact 
that mitochondria, as compared with the peroxisome, cannot oxi-
dize polyunsaturated fatty acids. Thus, under conditions of rapid 
triglyceride/FFA cycling and enhanced mitochondrial β-oxidation, 
polyunsaturated fatty acids would accumulate.
An increase in mitochondrial content, respiration, and fatty acid 
oxidation in WAT would be expected to cause a decrease in adi-
posity. Paradoxically, animals treated with rosiglitazone displayed 
a very small but significant increase in body weight, consistent 
with the known effect of PPARγ activation to induce adipogenesis. 
The increase in body weight was not accompanied by a detectable 
increase in the weight of the epididymal fat pads, suggesting that 
it may be due to fat accumulation in other depots. Interestingly, 
a “redistribution” of fat from visceral to peripheral depots has 
been observed to occur in response to treatment with thiazolidin-
ediones in rodents and humans (19–23). These results suggest the 
hypothesis that rosiglitazone produces two simultaneous effects: 
one to increase adipogenesis and second to increase fat utilization 
by increasing mitochondrial mass, fatty acid oxidation, and oxy-
gen consumption. These two effects may be differentially elicited 
in a depot-specific manner, leading to an overall increase in body 
weight while decreasing visceral adiposity. Further work will be 
required to directly test this hypothesis. Interestingly, pioglitazone 
has been reported to enhance daily profiles of energy expenditure 
and lipid utilization in diabetic rats with no changes in body 
weight (24), suggesting differences between animal models in the 
predominant responses to thiazolidinediones.
A link between insulin resistance and the mitochondrial oxida-
tive phosphorylation pathway has recently emerged in the analysis 
of genes expressed in human populations of insulin-resistant indi-
viduals (25, 26). Furthermore, insulin resistance in elderly patient 
populations is associated with striking decreases in mitochondrial 
oxidative phosphorylation (27). However, a causative link between 
decreased expression of genes that encode proteins involved in oxi-
dative phosphorylation and the development of insulin resistance 
has not been demonstrated. The results shown here support the 
Figure 7
Western blotting of mitochondrial proteins. Isolated adipocytes were 
lysed in sample buffer containing 1% SDS. Equal concentrations of 
total protein (20 μg) were analyzed by SDS-PAGE and Western blot-
ting using antibodies against mitochondrial (CytC, cytochrome c; COX, 
cytochrome oxidase subunit II; mHsp60) and non-mitochondrial (Chc, 
clathrin heavy chain; Actin) proteins. Except where indicated by the 
asterisk, all samples were from ob/ob mice with the ages and condi-
tions indicated. Band intensities were quantified using Photoshop 7 
software as described in Methods and were plotted. Similar results 
were obtained in three experiments.
Figure 6
Comparative analysis of mitochondrial protein expression in untreated and 
rosiglitazone-treated adipocytes. Mitochondria isolated from adipocytes 
from untreated (–) and rosiglitazone-treated (+) ob/ob mice were analyzed 
by sucrose gradient centrifugation and SDS-PAGE. Proteins exhibiting 
substantial differential expression in three independent experiments were 
excised and identified by mass spectrometry. Illustrated is one experiment 
from which the indicated proteins were excised. They are identified along 
the left margins by their respective gene symbols.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 114   Number 9   November 2004 1287
idea of such a causative role by demonstrating that a rosiglitazone, 
a prototypical member of a class of drugs that improve insulin sen-
sitivity and elicit alterations in mitochondrial proteins and in the 
cDNAs for mitochondrial genes that are nuclear encoded, would 
be predicted to enhance flow through the electron transport chain 
and oxidative phosphorylation.
Important insights into the mechanisms involved in the estab-
lishment of cellular mitochondrial mass have been obtained in 
recent years (28). Salient among these is the realization of the role 
of the transcriptional coactivator PGC-1 in the stimulation of the 
mitochondrial biogenesis program in brown fat and muscle cells 
(29). Despite the fact that endogenous PGC-1 levels are very low in 
WAT and that the interaction between PPARγ and PGC-1 has been 
thought to be ligand independent (30), it nevertheless is possible 
that rosiglitazone, by increasing the levels of PGC-1α and through 
activation of PPARγ, enhances coactivation of nuclear respiratory 
factors by the small amount of PGC-1 present, enough to induce 
expression of some mitochondrial genes, such as UCP-1. This 
in turn might lead to further expansion of mitochondrial mass 
through as-yet-unclear mechanisms (31). An increase in expres-
sion of brown fat–specific mitochondrial genes has been seen in 
response to exogenous insertion of PGC-1 into human adipocytes 
(32), consistent with the possibility that activation of PGC-1 in 
this tissue can enhance mitochondrial biogenesis and remodeling. 
Alternatively, additional PPARγ ligand–dependent mechanisms for 
induction of nuclear-encoded mitochondrial genes may remain to 
be discovered.
Methods
Animals. All procedures were carried out following guidelines of the Univer-
sity of Massachusetts Medical School Institutional Animal Care and Use 
Committee (UMMS-IACUC). The 4-week-old male ob/ob, 10-week-old male 
ob/ob, and 10-week-old male C57BL/6J mice were purchased from Jackson 
Laboratory and were housed (n = 4 per cage) under 12-hour light/dark 
cycles with ad libitum access to food and water. The 10-week-old mice were 
allowed to age to 26 weeks on standard pellet mouse chow. Prior to 26 weeks 
of age, half of the animals were treated with 0.375 mg/day of Avandia rosigl-
itazone maleate tablets (SmithKline Beecham Pharmaceuticals) for 14 days, 
delivered in powdered, standard lab mouse chow ad libitum. Rosiglitazone 
was ground in a coffee grinder and was added to the powdered mouse chow. 
Control animals not treated with rosiglitazone were given powdered stan-
dard lab chow ad libitum. Animals were made to fast overnight for 18 hours 
prior to tissue harvesting. Animals were sacrificed according to guidelines 
from UMMS-IACUC–approved protocols, and epididymal fat pads were 
harvested from the mice and placed in Krebs-Ringer solution buffered with 
HEPES (KRH), pH 7.4, supplemented with 2.5% BSA.
Blood glucose monitoring. Fasting blood glucose concentrations were 
determined from whole venous blood obtained from the pleural cav-
ity using the Accu-chek Advantage blood glucose monitoring system 
(Roche Diagnostics).
Primary fat cell isolation. Fat pads were weighed and cut into 0.3-cm3 
pieces with scissors and then were resuspended in KRH, pH 7.4, plus 
2.5% BSA containing 1 mg/ml collagenase (Worthington Biochemi-
cal Corp.). The fat pads were digested for 30–45 minutes at 37°C in an 
orbital bath shaking at 100 rpm. The digested samples were squeezed 
through chiffon material and the isolated cells were washed 3 times in 
KRH buffer, pH 7.4, plus 2.5% BSA.
Fluorescence microscopy. Adipocytes were washed two times in PBS and 
were fixed for 1 hour at 4°C in 4% formaldehyde in PBS. Cells were then 
permeabilized for 20 minutes at room temperature in PBS plus 0.5% Tri-
ton X-100 and then were blocked for 30 minutes at 4°C in PBS plus 0.5% 
Triton X-100 plus 1% FBS. Cells were incubated overnight at 4°C with the 
indicated primary antibodies in fresh blocking solution. Cells were washed 
with blocking solution and were incubated for 30 minutes at room tem-
perature with anti-mouse or anti-rabbit IgG HRP-conjugated secondary 
antibody (Promega). Cells were washed with PBS and were incubated for 15 
minutes at room temperature with 2 μg/ml DAPI stain. Cells were washed 
with PBS and mounted on slides using the Prolong Antifade Kit (Molecular 
Probes) and were imaged with a conventional wide-field microscope fitted 
with a 60× or 100× Nikon PlanApo objective. Stacks of 50 optical sections 
Figure 8
Fatty acid oxidation in isolated adipocytes. Adipocytes were isolated 
from 26-week-old untreated or rosiglitazone-treated ob/ob mice. 
Palmitate oxidation was estimated by the measurement of [14C]O2 
release over a 2-hour period as described in Methods. The numbers 
of cells present in 100 μl of packed volume, estimated by direct DNA 
measurements, were 5.4 × 105 and 5.1 × 105 in the absence and pres-
ence of rosiglitazone treatment, respectively.
Figure 9
Oxygen consumption in isolated adipocytes. Adipocytes were isolated 
from 4-week-old, 26-week-old untreated, or 26-week-old rosiglitazone-
treated ob/ob mice. Equal volumes of packed cells were separated into 
aliquots in wells of a 96-well BD Oxygen Biosensor plate. Plates were 
covered and fluorescence in each well was recorded over time with a 
Tecan SAFIRE multimode microplate spectrophotometer. The averages 
are plotted, and vertical lines represent the SEM of four independent 
experiments performed in triplicate. The number of cells contained in 
equal volumes was not statistically significantly between conditions.
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were obtained as described previously (5). For live cell imaging, isolated 
adipocytes were incubated at 37°C for 30 minutes with 100 nM MitoTrack-
er Green FM (Molecular Probes), a mitochondria-specific dye, and a single 
in-focus optical section was acquired. The fluorescence intensity of each cell 
was quantified with Photoshop 7 software by analyzing randomly selected 
regions of equal size within a single optical section using the marquee tool. 
Alternatively, stacks were projected into a single image plane and the total 
intensity per cell was recorded. The histogram function was then used to 
determine the number of pixels in the selected area, and this number was 
multiplied by the average pixel intensity. The average of these measurements 
was used to compare the average intensity among different cells.
RNA preparation for Affymetrix GeneChips. Total RNA was used for the 
preparation of cRNA from primary fat cells isolated from 4-week-old 
and 26-week-old mice and 26-week-old rosiglitazone-treated mice for use 
with MG-U74v2 GeneChips (Affymetrix). RNA from primary fat cells was 
prepared from three groups of 2–4 mice for each condition. Affymetrix 
protocols were followed for the preparation of cRNA from the mRNA or 
total RNA, which was hybridized according to Affymetrix instructions. The 
GeneChips were washed with a GeneChip Fluidics Station 400 and were 
scanned with an HP GeneArrayScanner (Affymetrix). The GeneChips were 
analyzed with MAS 5.0 (Affymetrix) and Microsoft Excel. Array data were 
sorted with Affymetrix Data Mining Tool Software and Microsoft Excel 
spreadsheets. Results analyzed are a composite of three independent exper-
iments. The expression level was determined using the average difference 
calculated by Affymetrix Microarray Suite 5.0 software. The “fold change” 
for each gene between 4-week-old ob/ob mice and 26-week-old untreated 
ob/ob mice was determined by dividing the mean of the average difference 
from three independent experiments of 4-week-old old ob/ob mice by the 
mean of the average difference from three independent experiments of 
26-week-old untreated ob/ob mice. The “fold change” for each gene between 
26-week-old untreated ob/ob mice and 26-week-old rosiglitazone-treated 
ob/ob mice was determined by dividing the mean of the average differ-
ence from three independent experiments of 26-week-old ob/ob mice by 
the mean of the average difference from three independent experiments of 
26-week-old rosiglitazone-treated ob/ob mice.
Northern blotting of PGC-1α. C57BL/6J ob/ob mice 11 weeks of age were 
housed (n = 4 per cage) under 12-hour light/dark cycles with ad libitum 
access to food and water. Animals were “mock-dosed” with vehicle alone by 
oral gavage for 4 days and then treated with either vehicle or 4 mg/kg/day of 
rosiglitazone in 0.25% weight/volume methylcellulose every day for 4 days. 
Epididymal white adipose depots were dissected and immediately homog-
enized in TRIzol reagent (Invitrogen Life Technologies). Total RNA was 
prepared with TRIzol reagent according to the manufacturer’s instructions. 
RNA (10 μg) was analyzed by Northern blotting with a 32P-labeled mouse 
PGC-1 cDNA fragment as a probe. The probe was generated by PCR of mouse 
adipose tissue cDNA using the following primers: PGC1F, 5′-CAAACCCA-
CAGAAAACAGGAA-3′, and PGC1R, 5′-TCCGTTTTGGAATTGAGTGAC-
3′. The PCR product was cloned into the pCR2.1-TOPO vector (Invitrogen) 
and the cDNA fragment was subsequently excised by digestion with EcoRI. 
The DNA probe was then radiolabeled with Ready-To-Go DNA Labelling 
Beads (-dCTP) (Amersham Biosciences) according to the manufacturer’s 
instructions and was purified with MicroSpin G-50 columns (Amersham 
Biosciences). Hybridization and washes were performed with QuikHyb solu-
tion (Stratagene) according to the manufacturer’s instructions.
Mitochondrial isolation. Adipocytes were rinsed twice in PBS and twice in 
isolation buffer (250 mM sucrose, 0.5 mM EGTA, and 5 mM HEPES, pH 
7.4). Cells were homogenized by ten “passes” of a motor-driven homogeniz-
er (500 rpm) and were centrifuged at 500 g for 10 minutes. The post-nuclear 
supernatant was removed and was centrifuged at 18,000 g for 25 minutes. 
The pellet was resuspended in 20% sucrose, 10 mM Tris, and 0.1 mM EDTA 
and was centrifuged at 18,000 g for 30 minutes. The pellet was resuspended 
in 60% sucrose, 10 mM Tris, and 0.05 mM EDTA. The suspension was over-
laid with a 53% sucrose layer (sucrose, 10 mM Tris, and 0.05 mM EDTA) 
and a 44% sucrose layer (sucrose, 10 mM Tris and 0.05 mM EDTA). The 
sucrose step gradient was centrifuged at 141,000 g for 2 hours. Purified 
mitochondria settled at the 44/53 interface. The mitochondrial layer was 
removed, diluted in isolation buffer, and centrifuged at 18,000 g for 30 
minutes. The mitochondrial pellet was suspended in 50 μl of isolation buf-
fer and a protein determination assay was performed with the Bradford 
assay (Bio-Rad Laboratories). 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate (CHAPS) detergent was added to the suspension to a 
final concentration of 6 mM CHAPS, the suspension was vortexed, and iso-
lation buffer was then added to bring the final concentration of CHAPS to 
3 mM. The suspension was vortexed continuously for 10 minutes, layered 
on top of a 1.9-ml 10–30% sucrose gradient, and spun at 114,000 g in a SW 
50.1 rotor (Beckman) at 4°C for 20 hours. The gradient was fractionated 
into ten 200-μl fractions, which were then analyzed by SDS-PAGE. Gels 
were then analyzed with Sypro Ruby protein stain (Molecular Probes).
Mass spectrometry. Proteins resolved by SDS-PAGE and visualized by 
Sypro Ruby protein stain were excised from the polyacrylamide gel and 
were digested in-gel with trypsin. The samples were analyzed by either 
electrospray ion-trap (ESI) mass spectrometry or matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. 
For analysis by ESI mass spectrometry, the digests were “run out” on a 
LC Packings UltiMate Nano HPLC (Mass Spectrometry International 
Ltd.) with a 100-μm C18PM column in a solvent A (0.1% formic acid and 
3.5% acetonitrile) and solvent B (0.1% formic acid in a 70:30 mixture of 
acetonitrile and water). Peptides were eluted with a linear gradient from 
100% solvent A to 60% solvent B in 40 minutes at a flow rate of 500 nano-
liters/minutes. Peptides were eluted directly into the LCQ Deca ESI (LC/
MS) mass spectrometer equipped with data-dependent acquisition and a 
high resolution scan performed. A higher-energy tandem mass spectrom-
etry (MS/MS) scan was performed after the initial scan for verification of 
peptide identification. The Affymetrix GeneChip database was searched 
for information on the presence and abundance of cDNAs encoding for 
the peptides identified in our study using the Sequest software developed 
by John Yates and Jimmy Eng at the University of Washington (Seattle, 
Washington, USA). For analysis by MALDI-TOF, the digested samples 
were further concentrated and desalted with Millipore Zip Tip C18 micro-
tips. Peptide masses were determined with a Kratos Analytical Axima CFR 
MALDI-TOF spectrometer equipped with a curved field reflectron. Peptide 
masses were “searched against” the nonredundant protein database using 
the Protein Prospector program MS-Fit, a program available at the website 
of the Mass Spectrometry Facility of the University of California at San 
Francisco. Fragmentation data from individual peptides via post-source 
decay analysis were “searched against” the nonredundant protein database 
using the Protein Prospector program MS-Tag.
Figure 10
PGC-1α expression in epididymal fat. Total RNA was prepared from fat 
pads from ob/ob mice before (–) and after (+) rosiglitazone treatment 
and was subjected to Northern blotting with a 32P-labeled mouse PGC-1 
cDNA fragment as a probe.
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Western blot analysis. Total cellular protein extracts were obtained by 
incubation of cells in 1% SDS in PBS and vortexing. Protein determina-
tion assays were performed with the Bradford assay (Bio-Rad). Equal con-
centrations of proteins were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane, which was blocked with 5% milk in Tris-buff-
ered saline with Tween-20 and incubated with indicated primary antibod-
ies (Figure 7). Membranes were then incubated with HRP-conjugated goat 
anti-mouse or anti-rabbit, detected by the Renaissance enhanced luminol 
reagent (NEN Life Science Products).
Fatty acid oxidation assay. Isolated adipocytes were washed in KRH plus 1% 
BSA buffer. Fresh buffer was added to the cells at a volume of two times the 
packed cell volume. Cells and buffer were inverted several times to make 
a homogenous mixture and equal aliquots of each sample were distrib-
uted into 50-ml polystyrene tubes. [14C]palmitic acid (Perkin Elmer Life 
Sciences) was added at a final concentration of 200 nCi/ml. An uncapped 
Eppendorf tube containing a piece of No. 1 Whatman filter paper soaked 
in 300 μl benzethonium hydroxide (Sigma-Aldrich) was placed inside each 
50-ml tube. Tubes were then sealed and incubated at 37°C for 2 hours. 
Tubes were gently shaken every 30 minutes during the incubation. After 
2 hours, 12 M HCl was added to the cells to release the [14C]O2, and each 
tube was resealed and incubated at 37°C overnight. The [14C]O2 released 
was measured by scintillation counting of the filter paper.
Oxygen consumption. Adipocytes isolated from 4-week-old ob/ob mice 
and 26-week-old untreated or rosiglitazone-treated ob/ob and C57BL/6J 
mice were washed in KRH buffer plus 1% BSA. Excess buffer was removed 
and 75 μl of floating packed cells from each condition were divided into 
aliquots in a BD Oxygen Biosensor System plate (BD Biosciences) in trip-
licate. Plates were sealed and “read” on a SAFIRE multimode microplate 
spectrophotometer (Tecan) at 1-minute intervals for 60 minutes at an 
excitation wavelength of 485 nm and emission wavelength of 630 nm.
Statistical analysis. Results were compared with Student’s t test. P values 
less than 0.05 were considered statistically significant.
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